CALIFORNIA LIFE SCIENCES for CALIFORNIA LIFE SCIENCES
What was lobbied
9 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Labor/HHS/Ed Appropriations: Drug Pricing, FDA, NIH, biodefense/pandemic, CDC, science/math education, and strategic stockpile funding and preparation; Coronavirus funding and response FDA Appropriations; PTO Appropriations. Drug Pricing proposals, Orphan Drug Tax Credit
| Lobbyist | Covered position, as disclosed |
|---|---|
| EVAN DORNER | — |
| OLIVER ROCROI | — |
Health Issues HCR
Support FDA user fee programs and review process consistency and predictability. Support FDA modernization practices. Support legislation proposing coverage for multicancer screening. Support FDA modernization efforts and vaccine awareness. Oppose domestic manufacturing/procurement mandates for pharmaceutical products, APIs, & medical devices. Support improvements to the Strategic National Stockpile for pandemic testing preparedness. Support public education campaign on pandemic preparedness. Support reauthorization of Rare Pediatric Disease Priority Review Voucher (RPD PRV) program. Oppose drug importation proposals. Oppose drug pricing proposals that allow Medicare to directly negotiate prices.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EVAN DORNER | — |
| OLIVER ROCROI | — |
Medicare/Medicaid MMM
Support reforms to enable Value Based Healthcare, including reforms to Anti-Kickback Statute & Stark Law. Oppose International Pricing Index/reference pricing in Medicare, including Most-Favored Nation (MFN) EO, and H.R. 3. Support ensuring patient access to/coverage of critical breakthrough products via Hospital Inpatient Prospective Payment System (IPPS) proposed and final rules, Hospital Outpatient Prospective Patient System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed and final rules, Medicare Coverage of Innovative Technology (MCIT) pathway proposed rule final rule implementation, and legislation. Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem. Oppose drug importation proposals. Oppose changes to Notice of Benefit and Payment Parameters (NBPP) final rule re cost-sharing assistance. Support expanded access to telehealth. Support value-based purchasing provision, but opposed line extensions and co-pay assistance provisions of CMS Medicaid VBP proposed rule.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EVAN DORNER | — |
| OLIVER ROCROI | — |
Taxation/Internal Revenue Code TAX
Support Research & Development and NOL tax incentives. Orphan Drug Tax Credits
| Lobbyist | Covered position, as disclosed |
|---|---|
| EVAN DORNER | — |
| OLIVER ROCROI | — |
Medical/Disease Research/Clinical Labs MED
Support NIH research funding. Support implementation of 21st Century Cures Act. Support implementation of MCIT rule.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EVAN DORNER | — |
| OLIVER ROCROI | — |
Copyright/Patent/Trademark CPT
Address concerns with provisions of patent litigation reform, including inter partes review. Support STRONGER Patents Act. Oppose "march-in" rights and "compulsory licensing" proposals. Support transferable exclusivity extensions to incentivize novel antibiotic Research & Development.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EVAN DORNER | — |
| OLIVER ROCROI | — |
Trade (domestic/foreign) TRD
Oppose proposals to reduce data exclusivity. Oppose proposals to restrict data uses.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EVAN DORNER | — |
| OLIVER ROCROI | — |
Defense DEF
Oppose domestic manufacturing/procurement mandates in NDAA for pharmaceutical products, APIs, & medical devices
| Lobbyist | Covered position, as disclosed |
|---|---|
| EVAN DORNER | — |
| OLIVER ROCROI | — |
Disaster Planning/Emergencies DIS
Support exemptions from California's COVID-19 stay-at-home order for the life sciences community.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EVAN DORNER | — |
| OLIVER ROCROI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.